Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2023 - 2024)
Ginkgo Bioworks Holdings (DNA) reported Asset Writedowns and Impairment of $47.9 million for Q2 2024, up 431.76% on a YoY basis from $9.0 million in Q3 2023, and down 60.58% quarter-over-quarter from $121.4 million in Q4 2023.
Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends
Ginkgo Bioworks Holdings has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $47.9 million in Q2 2024.
- For the quarter ending Q2 2024, Asset Writedowns and Impairment rose 431.76% year-over-year to $47.9 million; the trailing twelve-month figure through Sep 2025 stood at $47.9 million (down 83.01% YoY), and the FY2024 full-year result was $4.8 million, down 96.03% from the prior year.
- Asset Writedowns and Impairment for Q2 2024 stood at $47.9 million, down from $121.4 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $121.4 million in Q4 2023, with the low at $9.0 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 47.86 Mn |
| Jun 30, 2024 | 47.86 Mn |
| Dec 31, 2023 | 121.40 Mn |
| Dec 31, 2023 | 121.40 Mn |
| Sep 30, 2023 | 112.40 Mn |
| Sep 30, 2023 | 112.40 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Jun 30, 2023 | 9.00 Mn |